Potthast H, Dressman J B, Junginger H E, Midha K K, Oeser H, Shah V P, Vogelpoel H, Barends D M
Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, Bonn, Germany.
J Pharm Sci. 2005 Oct;94(10):2121-31. doi: 10.1002/jps.20444.
Literature data are reviewed on the properties of ibuprofen related to the biopharmaceutics classification system (BCS). Ibuprofen was assessed to be a BCS class II drug. Differences in composition and/or manufacturing procedures were reported to have an effect on the rate, but not the extent of absorption; such differences are likely to be detectable by comparative in vitro dissolution tests. Also in view of its therapeutic use, its wide therapeutic index and uncomplicated pharmacokinetic properties, a biowaiver for immediate release (IR) ibuprofen solid oral drug products is scientifically justified, provided that the test product contains only those excipients reported in this paper in their usual amounts, the dosage form is rapidly dissolving (85% in 30 min or less) in buffer pH 6.8 and the test product also exhibits similar dissolution profiles to the reference product in buffer pH 1.2, 4.5, and 6.8.
本文综述了与生物药剂学分类系统(BCS)相关的布洛芬的性质。布洛芬被评估为BCS II类药物。据报道,组成和/或生产工艺的差异会影响吸收速率,但不影响吸收程度;这种差异可能通过比较体外溶出试验检测到。此外,鉴于其治疗用途、较宽的治疗指数和简单的药代动力学性质,对于速释(IR)布洛芬固体口服药品,若试验产品仅含有本文中报道的常用量辅料,剂型在pH 6.8缓冲液中快速溶解(30分钟内溶解85%或更少),且试验产品在pH 1.2、4.5和6.8缓冲液中的溶出曲线与参比产品相似,则给予生物豁免在科学上是合理的。